Article

Deep Learning Modelling of Androgen Receptor Responses to Prostate Cancer Therapies

2020-01-16

Abstract excerpt

Gain-of-function mutations in human Androgen Receptor (AR) are amongst major causes of drug resistance in prostate cancer (PCa). Identifying mutations that cause resistant phenotype is of critical importance for guiding treatment protocols as well as for designing drugs that do not elicit adverse responses. However, experimental characterization of these mutations is time consuming and costly, and therefore predic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 89b8235a-21c1-59c2-94e6-fbceaaa08102
DOI: 10.1101/2020.01.15.908384

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Deep Learning Modelling of Androgen Receptor Responses to Prostate Cancer TherapiesDOI 10.1101/2020.01.15.908384Read

Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies.Semantic proximity Read

Deep Modeling of Gain-of-Function Mutations on Androgen ReceptorSemantic proximity Read

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer PatientsSemantic proximity Read

Biologically informed deep neural network for prostate cancer classification and discoverySemantic proximity Read

The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on TherapySemantic proximity Read

Pan-Cancer Drug Sensitivity Prediction from Gene Expression using Deep LearningSemantic proximity Read

In silico comparison between the mutated and wild-type androgen receptors and their influence on the selection of optimum androgenic receptor blockers for the treatment of prostate cancerSemantic proximity Read

In silico exploration of anti-prostate cancer compounds from differential expressed genesSemantic proximity Read

ATHENA: A deep learning–based AI for functional prediction of genomic mutations and synergistic vulnerabilities in prostate cancerSemantic proximity Read

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).Semantic proximity Read

N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive reviewSemantic proximity Read

Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids.Semantic proximity Read